Key facts
- Notable investors include Tech Incubator Program for Startup, Schmidt (South Korea), TAIL Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Atherosoft
- ·The full record, as it builds
Funding rounds
No funding rounds for Atherosoft are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atherosoft
Developer of AI-based intravascular ultrasound analysis software designed to support coronary assessment during interventional cardiology procedures. The company develops automated tools that analyze intravascular ultrasound data to identify plaque characteristics and anatomical features relevant to percutaneous coronary interventions, enabling clients to assess coronary anatomy and plaque characteristics during procedures using AI-based ultrasound analysis.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2025
- Website
- atherosoft.com/
- Ownership
- Privately Held (backing)
Atherosoft doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atherosoft shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atherosoft in its N-PORT filings yet. We sweep new filings monthly.